深度解读！神州控股获长城证券“增持”评级：持续深化“城市CTO+企业CSO”模式，驱动业务创新发展

神州控股获长城证券“增持”评级：持续深化“城市CTO+企业CSO”模式，驱动业务创新发展

北京 - 2024年6月14日 - 备受瞩目的中国领先综合企业服务商神州控股（00861.HK）今日获得长城证券首次评级，并给予“增持”评级。长城证券看好公司发展前景，预计其2024-2026年将分别实现营业收入192.55亿元、205.90亿元、222.08亿元，归母净利润4.91亿元、5.83亿元、7.43亿元。

此番评级充分体现了长城证券对神州控股未来发展潜力的信心。近年来，神州控股持续深化“城市CTO+企业CSO”模式，以创新模式驱动业务发展转型，取得了显著成效。

“城市CTO+企业CSO”模式：创新赋能，精准服务

“城市CTO+企业CSO”模式是神州控股为适应数字经济时代需求而创新提出的服务模式。该模式以城市为核心，以大数据、人工智能等技术为依托，为企业提供定制化、一体化的信息化解决方案，助力企业降本增效、转型升级。

具体而言，该模式通过设立城市CTO和企业CSO两个角色，为企业提供精准、高效的服务。城市CTO负责统筹规划城市信息化建设，企业CSO则负责深入企业，了解其具体需求，提供定制化解决方案。

深化模式落地，驱动业务增长

得益于“城市CTO+企业CSO”模式的有效落地，神州控股的大数据业务发展迅速。2023年，公司大数据产品及方案实现收入31.72亿元，同比增长30%，增速明显提升。同时，公司新签约订单46.45亿元，同比增长26%，已签未销订单22.55亿元，同比提升17%。

立足长远，持续创新

展望未来，神州控股将继续深化“城市CTO+企业CSO”模式，不断创新发展，为客户提供更加优质的服务。公司将聚焦大数据、人工智能、云计算等前沿技术，打造更多核心产品和解决方案，助力企业数字化转型升级，为中国经济社会发展贡献力量。

长城证券研报摘要

• 长城证券预计神州控股2024-2026年将分别实现营业收入192.55亿元、205.90亿元、222.08亿元，归母净利润4.91亿元、5.83亿元、7.43亿元。
• 看好公司“城市CTO+企业CSO”模式，认为该模式将持续驱动公司业务发展。
• 关注公司大数据业务发展，预计未来将保持高速增长。

神州控股简介

神州控股（00861.HK）是中国领先的综合企业服务商，致力于为企业提供信息化、数字化转型、供应链等服务。公司业务遍及中国大陆、香港、澳门、新加坡、马来西亚等地区，服务客户超过100万家。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.